17 November 2016 - NICE, like the NHS it supports, is looking at how to make big savings. One option is to get more ‘commercial’. 

NICE is in a financial tight spot. It is facing a 30% reduction in grant funding from the Department of Health by 2019/20. The Institute is already making savings, but there’s a lot more to do. It sees opportunities to recoup some of what they are losing from grant-in-aid from the DH from cost recovery for Technology Appraisals, income from NHS England for NICE work on the Cancer Drugs Fund, and Commissioning Support Documents as well as science policy and research grant income. Exploring ‘commercial’ income is another option.

Read Pharmaceutical Executive article